中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents

Screening for the etiology of non-cirrhotic splanchnic vein thrombosis should be taken seriously in clinical practice

DOI: 10.12449/JCH240101
More Information
  • Corresponding author: ZHUGE Yuzheng, yuzheng9111963@aliyun.com (ORCID: 0000-0002-3829-5831)
  • Received Date: 2023-11-22
  • Accepted Date: 2023-12-17
  • Published Date: 2024-01-23
  • Non-cirrhotic splanchnic vein thrombosis (NC-SVT) mainly includes portal vein thrombosis, superior mesenteric vein thrombosis, splenic vein thrombosis, and hepatic vein thrombosis (Budd-Chiari syndrome), and its prevalence rate is increasing with the increase in the incidence rates of related underlying diseases. Due to the harm of NC-SVT, there have been significant improvements in the awareness and ability for diagnosis among clinicians. However, anticoagulation and intervention therapies for thrombosis are often taken seriously in treatment, while the screening for risk factors or underlying diseases leading to SVT is ignored, which may affect the treatment outcome of thrombus in some patients and delay the diagnosis and treatment of the underlying disease. This article mainly introduces the acquired, hereditary, systemic, and local underlying diseases associated with the development of NC-SVT.

     

  • loading
  • [1]
    VALERIANI E, RIVA N, di NISIO M, et al. Splanchnic vein thrombosis: Current perspectives[J]. Vasc Health Risk Manag, 2019, 15: 449- 461. DOI: 10.2147/VHRM.S197732.
    [2]
    ELKRIEF L, PAYANCÉ A, PLESSIER A, et al. Management of splanchnic vein thrombosis[J]. JHEP Rep, 2023, 5( 4): 100667. DOI: 10.1016/j.jhepr.2022.100667.
    [3]
    HOW J, ZHOU A, OH ST. Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease[J]. Ther Adv Hematol, 2017, 8( 3): 107- 118. DOI: 10.1177/2040620716680333.
    [4]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
    [5]
    QI X, HAN G, GUO X, et al. Review article: The aetiology of primary Budd-Chiari syndrome-differences between the West and China[J]. Aliment Pharmacol Ther, 2016, 44( 11-12): 1152- 1167. DOI: 10.1111/apt.13815.
    [6]
    DENNINGER MH, CHAÏT Y, CASADEVALL N, et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors[J]. Hepatology, 2000, 31( 3): 587- 591. DOI: 10.1002/hep.510310307.
    [7]
    HOEKSTRA J, LEEBEEK FWG, PLESSIER A, et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: Findings from a cohort study[J]. J Hepatol, 2009, 51( 4): 696- 706. DOI: 10.1016/j.jhep.2009.06.019.
    [8]
    LANE DA, BAYSTON T, OLDS RJ, et al. Antithrombin mutation database: 2nd(1997) update. for the plasma coagulation inhibitors subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis[J]. Thromb Haemost, 1997, 77( 1): 197- 211.
    [9]
    PRIMIGNANI M, MANNUCCI PM. The role of thrombophilia in splanchnic vein thrombosis[J]. Semin Liver Dis, 2008, 28( 3): 293- 301. DOI: 10.1055/s-0028-1085097.
    [10]
    POISSON J, PLESSIER A, KILADJIAN JJ, et al. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study[J]. J Hepatol, 2017, 67( 3): 501- 507. DOI: 10.1016/j.jhep.2017.04.021.
    [11]
    PLOMPEN EPC, VALK PJM, CHU I, et al. Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis[J]. Haematologica, 2015, 100( 6): e226- e228. DOI: 10.3324/haematol.2014.120857.
    [12]
    MURAD SD, PLESSIER A, HERNANDEZ-GUERRA M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome[J]. Ann Intern Med, 2009, 151( 3): 167- 175. DOI: 10.7326/0003-4819-151-3-200908040-00004.
    [13]
    SØGAARD KK, FARKAS DK, PEDERSEN L, et al. Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival[J]. Blood, 2015, 126( 8): 957- 963. DOI: 10.1182/blood-2015-03-631119.
    [14]
    KIM AS, KHORANA AA, MCCRAE KR. Mechanisms and biomarkers of cancer-associated thrombosis[J]. Transl Res, 2020, 225: 33- 53. DOI: 10.1016/j.trsl.2020.06.012.
    [15]
    KANELLOPOULOU T, ALEXOPOULOU A, THEODOSSIADES G, et al. Pylephlebitis: An overview of non-cirrhotic cases and factors related to outcome[J]. Scand J Infect Dis, 2010, 42( 11-12): 804- 811. DOI: 10.3109/00365548.2010.508464.
    [16]
    de STEFANO V, MARTINELLI I. Splanchnic vein thrombosis: Clinical presentation, risk factors and treatment[J]. Intern Emerg Med, 2010, 5( 6): 487- 494. DOI: 10.1007/s11739-010-0413-6.
    [17]
    BAIGES A, PROCOPET B, SILVA-JUNIOR G, et al. Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis[J]. J Hepatol, 2023, 78( 1): 114- 122. DOI: 10.1016/j.jhep.2022.08.023.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (235) PDF downloads(87) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return